Topic:

Venture Capital

Latest Headlines

Latest Headlines

Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA

A few months after raising $357 million to back their new biotech investment group, the ex-Elan team at Malin has helped place a $67 million bet on Melinta Therapeutics, a late-stage antibiotics developer now taking a second stab at a pivotal Phase III study of their lead program.

Clarus adds a $500M biotech venture fund as the good times roll

Clarus Ventures announced this morning that it had raised $500 million for its third biotech fund, Clarus III, easily beating its goal of $375 million. That money will now be devoted to new investments ranging from $15 million to $50 million for companies focused on breakthrough--or at least best-in-class--drugs or new R&D risk-sharing projects with biotechs and pharmas.

Celtaxsys banks $45M for its cystic fibrosis drug

Atlanta-headquartered biotech Celtaxsys raised $45 million in Series D cash, plotting to kick off a Phase II study for its lead drug, an anti-inflammatory treatment for cystic fibrosis.

UPDATED: Patriots owner Kraft teams up on a $30M antibiotics round for Spero

Atlas Venture's antibiotics upstart Spero Therapeutics has rounded up a $30 million B round, banking enough cash to steer its in-house pipeline to the clinic with some in-licensed technology while shepherding its Roche-partnered program through an IND.

Soon-Shiong raises $75M for another oncology player in his murky empire

It seems not a month goes by without billionaire entrepreneur Patrick Soon-Shiong striking a deal to expand his sprawling family of cancer-focused startups. This time, the recently launched NantCell has raised $75 million in equity, pressing forward in immuno-oncology with some in-licensed treatments.

SV Life Sciences sets out for $400M to fuel biotech bets

Biotech investor SV Life Sciences is out raising a 6th fund, looking for $400 million as it gears up for another round of bets on startups.

Mapi Pharma closes $10M Series A round after two scuttled IPOs

Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash in a Nasdaq IPO.

A well-connected Pronutria revs up amino acid research with $39M C round

Cambridge, MA-based Pronutria, a graduate of Flagship's VentureLabs that recently attracted some high-profile R&D talent, has put the finishing touches to a $39 million C round designed to advance a pipeline of therapeutic-strength amino acid drugs in the clinic.

HIV biotech Calimmune bags $15M to move one-time gene therapy into new trials

After getting started 9 years ago with backing from angel investors, Calimmune just landed a $15 million B round, positioning the biotech to move into the clinic with a gene therapy designed to durably stymie the lethal HIV with one treatment.

Can PureTech and its high-profile board raise $160M in London?

Boston-based PureTech, an investment group which is better known for its high-profile board than its portfolio of upstart life sciences companies, has landed in the U.K. with a plan to raise $160 million on the London stock market.